FIELD: medicine.
SUBSTANCE: group of inventions relates to methods of treating or preventing disorders of the liver, bile ducts and pancreas. A method of treating or preventing a liver disease or disorder selected from a group consisting of toxic liver damage, alcoholic or non-alcoholic fatty liver disease (NAFLD), hepatic cirrhosis, hepatic insufficiency, hepatic fibrosis, liver sclerosis, hepatic encephalopathy, non-alcoholic steatohepatitis (NASH), wherein said method comprises administering an effective amount of α-defensin and/or β-defensin of mammals selected from a group consisting of hBD-2 (SEQ ID NO: 5), truncated hBD2 (SEQ ID NO: 17), hBD-1 (SEQ ID NO: 4), hBD-3 (SEQ ID NO: 6), and hBD-4 (SEQ ID NO: 7), β-defensin, which differs from hBD1, hBD2, hBD3, hBD4, or truncated hBD2 (SEQ ID NO: 17) by less than 5 conserved amino acid substitutions, HD5 (SEQ ID NO: 8), and/or HD6 (SEQ ID NO: 9), a subject in need thereof. Also disclosed are a method of treating or preventing a biliary disease or disorder, a method of treating or preventing a disease or a pancreatic disorder, method of treating or preventing a metabolic disease or disorder, using α-defensin and/or β-defensin in mammals in a method of treating and preparing a medicinal agent.
EFFECT: treatment of liver, bile duct and pancreatic disorders is offered.
35 cl, 38 dwg, 10 ex
Title |
Year |
Author |
Number |
METHODS FOR MODULATING INTESTINAL MICROBIOTA |
2017 |
- Nordkild, Peter
- Wehkamp, Jan
- Kjaerulff, Soren
|
RU2738265C2 |
COMPOSITION AND USE OF ARGININE-DEPLETING AGENTS IN CANCER, OBESITY, METABOLIC DISORDERS AND RELATED COMPLICATIONS AND COMORBIDITIES |
2019 |
- Leng, Yun Chun
- Shum, Alisa Sau-Vun
|
RU2826185C2 |
COMPOSITIONS AND METHODS FOR CONTROLLING ACCUMULATION OF ADIPOSE TISSUE |
2014 |
- Vulf M. Majkl
- Bojlan Majkl O.
|
RU2711478C2 |
COMPOSITION FOR PREVENTING, IMPROVING OR TREATING OBESITY OR FATTY LIVER DISEASE CONTAINING LEUCONOSTOC CITREUM WiKim0104 |
2020 |
- Choj, Khak Jong
- Lim, Seul-Ki
|
RU2816754C2 |
USE OF COMPOSITIONS CONTAINING BIFIDOBACTERIUM ANIMALIS SSP. LACTIS LMG P-28149 |
2015 |
- Kentan Zhoan
- Linart Van Lidt De Jede Ekhan
- Granzhett Korinn
- Po Bryuno
- Makki Kassem
- Volevchuk Izabell
- Alar Zhann
- Lerter-Valanti Veronik
|
RU2673341C2 |
FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE |
2020 |
- Dun, Chzhao
- Chzhou, Chi
- Chzhan, Tsziyu
- Li, Yuanli
- Li, Tsyan
|
RU2804335C2 |
STRAIN OF AKKERMANSIA MUCINIPHILA AND APPLICATION THEREOF |
2019 |
- Ko, Gwang Pyo
- Yoon, Hyo Shin
- Cho, Chung Hwan
- You, Hyun Ju
- Nam, Tae Wook
|
RU2777068C1 |
COMPOSITION FOR HYPERLIPIDEMIA TREATMENT CONTAINING OXYNTOMODULIN DERIVATIVE |
2013 |
- Chun Sun Yub
- Kim Chin-Sun
- Dzhan Myun Khyun
- Li San Khyun
- Chkhoj In Yung
- Kvon Se Chan
|
RU2642267C2 |
AKKERMANSIA MUCINIPHILA STRAIN AND ITS APPLICATION |
2019 |
- Ko, Gwang Pyo
- Yoon, Hyo Shin
- Cho, Chung Hwan
- You, Hyun Ju
- Nam, Tae Wook
|
RU2792651C2 |
TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES |
2018 |
- Guz, Elvire
- Garsiya, Stefani
|
RU2794170C2 |